will be collected and laid on the Table of the Rajya Sabha.

(f) and (g) The Supreme Court in its judgement on 10th April, 1987 has observed that profiteering in life saving drugs is diabolic and is a menace which has to be fettered and curbed. The judgement is being examined.

Statement

Sl. No.	Name of the company	Name of the bulk drug/formulation
1	M/s. Glaxo Labs. I. Ltd.	Betamethasone and its formulations.
2	M/s Cynamid India Ltd.	Tetracyclines & formaulations and Diethyl Carbamazine formulations.
3	M/s. Hoechst India Ltd	Baralgan, Pyrolidine Methyl Tetracycline, Pheniramine, Glybenclamide Frusemid and formulations.
4	M/s. Pfizer Ltd.	Oxytetracycline, PAS and its salts and formulations based thereon.
5	M/s. Merind Ltd.	Dexamethasone and its formulations.

Marketing of essential medicines by drug companies

1508. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRRY be pleased to state:

(a) whether it is a fact that certain companies were found marketing certain essential medicines falling under Category I and II under other categories;

(b) if so, what are the names of those companies alongwith the name of each product;

(c) whether his Ministry has worked out the prices of those medicines as per correct mark up;

(d) if so, what is the price worked out and price being charged on each product alongwith percentage increase in each case;

(e) whether his Ministry issued a claim of difference;

(f) if so, what is the amount of claim on each product;

(g) whether his Ministry has worked out interest on that amount;

(h) if so, at what rate and if not, what are the reasons therefor;

(i) whether his Ministry has taken any penal action against those drug companies; and

(j) if so, what are the details thereof and if not, what are the reasons therefor?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRAR SINGH): (a) No, Sir.

(b) to (j) Do not arise.

Multinational bias of New Drug Policy

1509. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the convention of the various sections of drug industry have considered the New Drug Policy as multinational oriented; and